2025-522750-39-00已完成3 期
A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D
Cinclus Pharma Holding AB (publ)70 个研究点 分布在 6 个国家目标入组 96 人开始时间: 2026年4月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 96
- 试验地点
- 70
- 主要终点
- 1.Maintained healing of EE after 24 weeks as assessed by central reading of endoscopy.
研究概览
简要总结
To confirm non-inferiority of linaprazan glurate ‘high dose’ compared to lansoprazole in the maintenance of healing of all grades of EE due to GERD after 24 weeks of maintenance treatment
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •An individual who has participated in a preceding linaprazan glurate healing trial will be asked to participate in this trial if the following criteria apply:
- •The participant understands and voluntarily signs an Informed Consent Form (ICF) prior to initiation of any trial-related assessments/procedures.
- •The participant has a healed EE as assessed by central review of endoscopic examination either from the last regular visit in a preceding phase 3 healing trial OR from the Run-in Period to the present maintenance trial.
- •The participant is willing and able to comply with all aspects of the protocol (including endoscopies, tablet and capsule swallowing, electronic device [e-device] completion, etc.).
排除标准
- •An individual who has participated in a preceding linaprazan glurate phase 3 healing trial can be enrolled in this maintenance trial unless they meet any of the following exclusion criteria:
- •EE as graded from the endoscopy during the Run-in Period (only applicable for participants with previous endoscopy >14 days before the last regular visit in the preceding healing trial).
- •Current or history of alcohol, drug abuse, and/or use of androgens/anabolic steroids (testosterone and testosterone esters [enanthate, undecanoate, cypionate], methyltestosterone, oxandrolone, stanozolol, fluoxymesterone, danazol, tetrahydrogestrinone, 7α-methyl-19-nortestosterone) within 2 years prior to Run-in Period. Stable androgen substitution treatment for male hypogonadism is allowed.
- •Women who are pregnant or breast feeding
- •Individual is an employee of the Investigator, trial site, Sponsor, or Contract Research Organization (CRO) with direct involvement in the proposed trial or other trials under the direction of that Investigator, trial site, Sponsor, or CRO, as well as family members of the employee of the Investigator, trial site, Sponsor, or CRO.
- •Individuals who have previously participated (completed or withdrawn) in this trial.
- •A female participant of childbearing potential who is or may be sexually active with a non-sterilized male partner and who is unwilling to routinely use highly effective contraception from the signing of the ICF until 7 days after the last dose of IP.
- •A male participant with a partner of childbearing potential who is unwilling to routinely use highly effective contraception and is unwilling to agree to not father a child from the signing of the ICF until at least 7 days after the last dose of IP.
- •Solitary esophageal ulcer in the proximal two-thirds of the esophagus, untreated Barrett’s esophagus or any other condition affecting the esophagus, including eosinophilic esophagitis; esophageal varices; viral or fungal infection; esophageal stricture.
- •Significant noncompliance with protocol-specified procedures or treatment in the preceding healing trial as judged by the Investigator.
- •Adverse event (AE) resulting in premature discontinuation of IP in the preceding healing trial.
- •History or presence of any clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, neurological disease or disorder, or psychiatric diagnosis which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or influence the trial results or the participant’s ability to participate in the trial. The following examples are conditions that would exclude the participant from participating: a. History of myocardial infarction/ acute coronary syndrome within 3 months prior to the M0 visit b. History of ventricular arrhythmia or implanted cardioverter defibrillator c. Symptomatic congestive heart failure (New York Heart Association [NYHA] class 3-4) d. Family history of/ diagnosis of hereditary arrhythmia syndrome
- •History of adult asthma that required intensive treatment in an emergency room
- •Any planned major surgery within 52 weeks of the Run-in Period.
- •Any clinically significant laboratory parameter outside reference value that has occurred since Screening or Baseline values in the preceding healing trial and which, in the opinion of the Investigator, may suggest a new or insufficiently understood disease, may present an unreasonable risk to the participant as a result of his/her participation in the trial, or may interfere with trial assessments. The below laboratory test results during the Run-in Period* (HX/M0 visit) are exclusionary: a. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 × upper limit of normal (ULN) for the central laboratory conducting the test. b. Serum total bilirubin (TBL) >1.5 × ULN for the central laboratory conducting the test. (individuals with Gilbert’s syndrome can be included). *Note: One retest is allowed during the Run-in Period.
- •Enrollment in another interventional clinical trial, except for ongoing participation in an EE healing trial with linaprazan glurate.
研究组 & 干预措施
LANSOPRAZOLE, LANSOPRAZOLE
Comparator
干预措施: LANSOPRAZOLE (Drug)
Linaprazan glurate
Test
干预措施: Linaprazan glurate (Drug)
Placebo to match Linaprazan Glurate
Placebo
干预措施: Placebo to match Linaprazan Glurate (Drug)
Placebo to match lansoprazole high dose, Placebo to match Lansoprazole low dose
Placebo
干预措施: Placebo to match lansoprazole high dose (Drug)
Placebo to match lansoprazole high dose, Placebo to match Lansoprazole low dose
Placebo
干预措施: Placebo to match Lansoprazole low dose (Drug)
结局指标
主要结局
1.Maintained healing of EE after 24 weeks as assessed by central reading of endoscopy.
1.Maintained healing of EE after 24 weeks as assessed by central reading of endoscopy.
次要结局
- 1. Maintained healing of EE after 24 weeks as assessed by central reading of endoscopy
- 2. Maintained healing from EE as assessed by central reading of endoscopy after 24 weeks in participants with Baseline EE due to GERD of LA grades C/D.
- 3. Percentage of heartburn-free days from Baseline to Week 24 based on electronic Diary
- 4. Maintained healing of EE comparing linaprazan glurate ‘high dose’ with lansoprazole after 52 weeks as assessed by central reading of endoscopy.
- 5. Maintained healing of EE comparing linaprazan glurate ‘low dose’ with lansoprazole after 52 weeks as assessed by central reading of endoscopy
研究者
Rikard Reneland
Scientific
Cinclus Pharma Holding AB (publ)
研究点 (70)
Loading locations...
相似试验
撤回
3 期
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)NCT07313774Cinclus Pharma Holding AB1,050
招募中
3 期
A randomized, phase 3 multicenter study to confirm the clinical efficacy of linaprazan glurate compared to lansoprazole in participants with erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)2024-518714-31-00Cinclus Pharma Holding AB (publ)382
已完成
Phase 3 4
Cariprazine as an add on agent in depression patients.CTRI/2024/10/076064Dr Shreya Agrawal60
尚未招募
不适用
Comparing Vonoprazan and Omeprazole for Healing Stomach UlcersCTRI/2025/07/091209Dr Bazla Nazir100
已完成
1 期
Drug Interaction Study on Linaprazan Glurate CapsulesNCT07294846Jiangsu Sinorda Biomedicine Co., Ltd56